Talphera, Inc. (TLPH)
USD 0.49
(-13.84%)
USD 0.49
(-13.84%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.72 Million USD | 42.28% |
| 2022 | -9.91 Million USD | -190.45% |
| 2021 | 10.95 Million USD | 754.21% |
| 2020 | -1.67 Million USD | -101.56% |
| 2019 | 107.1 Million USD | 505.3% |
| 2018 | 17.69 Million USD | -64.46% |
| 2017 | 49.78 Million USD | 249.94% |
| 2016 | 14.22 Million USD | 160.83% |
| 2015 | -23.38 Million USD | 33.49% |
| 2014 | -35.16 Million USD | 52.5% |
| 2013 | -74.03 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -6.89 Million USD | -18.73% |
| 2024 Q1 | -5.8 Million USD | -1.52% |
| 2023 FY | -5.72 Million USD | 42.28% |
| 2023 Q3 | -13.38 Million USD | -80.69% |
| 2023 Q4 | -5.72 Million USD | 57.27% |
| 2023 Q1 | -9.98 Million USD | -1.34% |
| 2023 Q2 | -7.41 Million USD | 25.78% |
| 2022 Q2 | -5.77 Million USD | -107.27% |
| 2022 Q4 | -9.85 Million USD | -87.37% |
| 2022 FY | -9.91 Million USD | -190.45% |
| 2022 Q1 | 79.4 Million USD | -12.97% |
| 2022 Q3 | -5.25 Million USD | 8.98% |
| 2021 Q3 | 93.1 Million USD | 11.91% |
| 2021 Q4 | 91.24 Million USD | -2.0% |
| 2021 Q2 | 83.19 Million USD | 13.42% |
| 2021 Q1 | 73.35 Million USD | -14.39% |
| 2021 FY | 10.95 Million USD | 754.21% |
| 2020 Q4 | 85.67 Million USD | -10.65% |
| 2020 FY | -1.67 Million USD | -101.56% |
| 2020 Q1 | 96.39 Million USD | -9.18% |
| 2020 Q3 | 95.88 Million USD | -1.69% |
| 2020 Q2 | 97.53 Million USD | 1.19% |
| 2019 Q3 | 99.16 Million USD | 73.77% |
| 2019 Q2 | 57.06 Million USD | 56.95% |
| 2019 Q1 | 36.36 Million USD | 105.49% |
| 2019 FY | 107.1 Million USD | 505.3% |
| 2019 Q4 | 106.13 Million USD | 7.03% |
| 2018 Q4 | 17.69 Million USD | -63.46% |
| 2018 FY | 17.69 Million USD | -64.46% |
| 2018 Q3 | 48.43 Million USD | -32.44% |
| 2018 Q2 | 71.68 Million USD | 19.15% |
| 2018 Q1 | 60.16 Million USD | 20.85% |
| 2017 Q1 | 24.83 Million USD | 74.55% |
| 2017 Q3 | 35.3 Million USD | -7.05% |
| 2017 Q4 | 49.78 Million USD | 41.02% |
| 2017 Q2 | 37.98 Million USD | 52.95% |
| 2017 FY | 49.78 Million USD | 249.94% |
| 2016 Q2 | -8.32 Million USD | 55.0% |
| 2016 Q4 | 14.22 Million USD | 2443.66% |
| 2016 Q3 | -607 Thousand USD | 92.7% |
| 2016 FY | 14.22 Million USD | 160.83% |
| 2016 Q1 | -18.48 Million USD | 20.95% |
| 2015 Q4 | -23.38 Million USD | -81.87% |
| 2015 Q2 | -12.71 Million USD | 47.05% |
| 2015 FY | -23.38 Million USD | 33.49% |
| 2015 Q3 | -12.86 Million USD | -1.18% |
| 2015 Q1 | -24 Million USD | 31.74% |
| 2014 FY | -35.16 Million USD | 52.5% |
| 2014 Q4 | -35.16 Million USD | 22.5% |
| 2014 Q1 | -63.09 Million USD | 14.78% |
| 2014 Q2 | -53.09 Million USD | 15.86% |
| 2014 Q3 | -45.37 Million USD | 14.54% |
| 2013 Q3 | -50.27 Million USD | -427.61% |
| 2013 Q1 | -22.87 Million USD | 0.0% |
| 2013 FY | -74.03 Million USD | 0.0% |
| 2013 Q4 | -74.03 Million USD | -47.26% |
| 2013 Q2 | -9.52 Million USD | 58.34% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 106.073% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 107.633% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 101.314% |
| Cosmos Health Inc. | 8.59 Million USD | 166.595% |
| Dynavax Technologies Corporation | 106.63 Million USD | 105.365% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 95.627% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 101.322% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 63.408% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 63.408% |
| SCYNEXIS, Inc. | -19.35 Million USD | 70.434% |
| Safety Shot Inc | -2.28 Million USD | -150.44% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 39.33% |
| Alpha Teknova, Inc. | 1.97 Million USD | 389.818% |
| Bright Green Corporation | 1.84 Million USD | 410.633% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 101.247% |
| Embecta Corp. | 1.31 Billion USD | 100.436% |
| PainReform Ltd. | -7.95 Million USD | 28.038% |
| Journey Medical Corporation | -9.7 Million USD | 41.075% |
| Procaps Group, S.A. | 242.93 Million USD | 102.355% |
| Theratechnologies Inc. | 24.87 Million USD | 123.003% |
| Harrow Health, Inc. | 116.41 Million USD | 104.914% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -127.024% |
| Biofrontera Inc. | 4.05 Million USD | 241.05% |
| DURECT Corporation | -7.65 Million USD | 25.255% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 82.936% |
| Cronos Group Inc. | -663.32 Million USD | 99.138% |
| OptiNose, Inc. | 58.06 Million USD | 109.853% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 100.918% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 60.74% |
| RedHill Biopharma Ltd. | -5.18 Million USD | -10.316% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 138.107% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 10.042% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 5453.784% |
| Radius Health, Inc. | 359.28 Million USD | 101.592% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 3000.983% |
| ProPhase Labs, Inc. | 19.23 Million USD | 129.749% |
| Phibro Animal Health Corporation | 454.84 Million USD | 101.258% |
| Procaps Group S.A. | 242.93 Million USD | 102.355% |
| Alvotech | 1.06 Billion USD | 100.538% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 255.546% |
| Viatris Inc. | 17.13 Billion USD | 100.033% |
| Rockwell Medical, Inc. | 4.45 Million USD | 228.389% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -17.306% |
| SIGA Technologies, Inc. | -148.68 Million USD | 96.152% |
| Tilray Brands, Inc. | 158.97 Million USD | 103.599% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 104.693% |
| Shineco, Inc. | 29.29 Million USD | 119.532% |
| PetIQ, Inc. | 351.93 Million USD | 101.626% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -97.179% |
| Incannex Healthcare Limited | -5.48 Million USD | -4.303% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 103.227% |
| Alimera Sciences, Inc. | 55.3 Million USD | 110.344% |
| Silver Spike Investment Corp. | -32.61 Million USD | 82.457% |
| Assertio Holdings, Inc. | -32.52 Million USD | 82.413% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -284.289% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -13.055% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | -18.841% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 30.346% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 235.665% |
| Hempacco Co., Inc. | 13.61 Million USD | 142.021% |
| Alvotech | 1.06 Billion USD | 100.538% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 180.07% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 94.084% |
| Currenc Group, Inc. | -16.57 Million USD | 65.48% |
| Kamada Ltd. | -46.43 Million USD | 87.679% |
| Indivior PLC | -33.95 Million USD | 83.15% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 2295.538% |
| Flora Growth Corp. | -713 Thousand USD | -702.384% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 30.346% |
| Evolus, Inc. | 63.7 Million USD | 108.98% |
| HUTCHMED (China) Limited | -197.45 Million USD | 97.103% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 101.194% |
| Akanda Corp. | 3.9 Million USD | 246.508% |